S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
Sell every Stock except ONE (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Sell every Stock except ONE (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
Sell every Stock except ONE (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
Sell every Stock except ONE (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Sell every Stock except ONE (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
Sell every Stock except ONE (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
Sell every Stock except ONE (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Sell every Stock except ONE (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
Sell every Stock except ONE (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
Sell every Stock except ONE (Ad)
As Elizabeth Holmes heads to prison for fraud, many puzzle over her motives
New bill to build Athletics stadium on Las Vegas Strip caps Nevada's cost at $380 million
Sell every Stock except ONE (Ad)
Mechanical sails? Batteries? Shippers forming 'green corridors' to fast-track cleaner technologies
Baby eels remain one of America's most valuable fish after strong year in Maine
Sell every Stock except ONE (Ad)
Teen workers are in high demand for summer and commanding better pay
Biden, GOP reach tentative deal to raise debt ceiling, avoid calamitous US default
NASDAQ:DRTS

Alpha Tau Medical (DRTS) Stock Forecast, Price & News

$3.87
+0.09 (+2.38%)
(As of 05/26/2023 ET)
Compare
Today's Range
$3.78
$3.94
50-Day Range
$2.76
$3.98
52-Week Range
$2.75
$12.50
Volume
18,562 shs
Average Volume
51,883 shs
Market Capitalization
$267.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50

Alpha Tau Medical MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
171.3% Upside
$10.50 Price Target
Short Interest
Healthy
0.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.16mentions of Alpha Tau Medical in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.46) to ($0.49) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

Medical Sector

706th out of 1,018 stocks

Surgical & Medical Instruments Industry

75th out of 105 stocks


DRTS stock logo

About Alpha Tau Medical (NASDAQ:DRTS) Stock

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Receive DRTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alpha Tau Medical and its competitors with MarketBeat's FREE daily newsletter.

DRTS Stock News Headlines

AI Creates New Cancer Drug - In Just 30 Days!
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
Recap: Alpha Tau Medical Q1 Earnings
Alpha Tau Medical Ltd (DRTS) Receives a Buy from H.C. Wainwright
Bank Collapse Causes Gold Prices to Soar
Silicon Valley Bank was the second-largest bank in American history to fail, and investors have started piling into the safety and security of gold. But if you're not taking advantage of a little-known way to invest for around $5 today, you're missing out.
Alpha Tau Medical (DRTS) and Its Rivals Critical Survey
Analyzing Alpha Tau Medical (DRTS) & Its Rivals
Reviewing Alpha Tau Medical (DRTS) and The Competition
DRTS Alpha Tau Medical Ltd.
See More Headlines
Receive DRTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alpha Tau Medical and its competitors with MarketBeat's FREE daily newsletter.

DRTS Company Calendar

Last Earnings
3/09/2023
Today
5/27/2023
Next Earnings (Estimated)
8/24/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DRTS
Fax
N/A
Employees
83
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.50
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+171.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-33,760,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.43 per share

Miscellaneous

Free Float
41,826,000
Market Cap
$267.53 million
Optionable
Not Optionable
Beta
1.04

Key Executives

  • Mr. Uzi Sofer (Age 53)
    CEO & Chairman
  • Mr. Raphi Levy (Age 38)
    Chief Financial Officer
  • Mr. Amnon Gat (Age 48)
    Chief Operations Officer
  • Mr. Ronen Segal (Age 50)
    Chief Technology Officer
  • Prof. Yona Keisari (Age 76)
    Chief Scientific Officer & Member of Scientific Advisory board
  • Ms. Rebecca Becker
    VP of legal
  • Mr. Peter M. Melnyk (Age 61)
    Chief Commercial Officer
  • Dr. Robert B. Den M.D. (Age 44)
    Chief Medical Officer & Member of Scientific Advisory Board
  • Prof. Itzhak Kelson (Age 83)
    Chief Physics Officer & Member of Scientific Advisory Board
  • Ms. Yael Zeiger (Age 40)
    Corp. Controller













DRTS Stock - Frequently Asked Questions

Should I buy or sell Alpha Tau Medical stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alpha Tau Medical in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DRTS shares.
View DRTS analyst ratings
or view top-rated stocks.

What is Alpha Tau Medical's stock price forecast for 2023?

2 brokerages have issued 1 year price objectives for Alpha Tau Medical's shares. Their DRTS share price forecasts range from $9.00 to $12.00. On average, they predict the company's share price to reach $10.50 in the next twelve months. This suggests a possible upside of 171.3% from the stock's current price.
View analysts price targets for DRTS
or view top-rated stocks among Wall Street analysts.

How have DRTS shares performed in 2023?

Alpha Tau Medical's stock was trading at $3.18 at the beginning of 2023. Since then, DRTS stock has increased by 21.7% and is now trading at $3.87.
View the best growth stocks for 2023 here
.

When is Alpha Tau Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 24th 2023.
View our DRTS earnings forecast
.

How were Alpha Tau Medical's earnings last quarter?

Alpha Tau Medical Ltd. (NASDAQ:DRTS) announced its earnings results on Thursday, March, 9th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.08.

What ETF holds Alpha Tau Medical's stock ?

BlueStar Israel Technology ETF holds 66,326 shares of DRTS stock, representing 0.19% of its portfolio.

What is Alpha Tau Medical's stock symbol?

Alpha Tau Medical trades on the NASDAQ under the ticker symbol "DRTS."

Who are Alpha Tau Medical's major shareholders?

Alpha Tau Medical's stock is owned by many different retail and institutional investors. Top institutional investors include ETF Managers Group LLC (0.10%), ProVise Management Group LLC (0.05%), Geode Capital Management LLC (0.04%) and Circle Wealth Management LLC (0.02%).

How do I buy shares of Alpha Tau Medical?

Shares of DRTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alpha Tau Medical's stock price today?

One share of DRTS stock can currently be purchased for approximately $3.87.

How much money does Alpha Tau Medical make?

Alpha Tau Medical (NASDAQ:DRTS) has a market capitalization of $267.53 million. The company earns $-33,760,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis.

How can I contact Alpha Tau Medical?

Alpha Tau Medical's mailing address is 301 N. MARKET STREET STE 1414, WILMINGTON DE, 19801. The official website for the company is healthcarecapitalcorp.com. The company can be reached via phone at 972-3577-4115 or via email at ir@alphatau.com.

This page (NASDAQ:DRTS) was last updated on 5/27/2023 by MarketBeat.com Staff

My Account -